Synergistic inhibitory effects of transplatin and β-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor

Cancer Letters

Volumn 188, Issue 1-2, 2002, Pages 67-72

  Xu, Ying ^a   Nakajo, Shigeo ^a   Nakaya, Kazuyasu ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Hydroxyisovalerylshikon; Epidermal growth factor; Synergism; Transplatin; v Src

Indexed keywords

ANTINEOPLASTIC AGENT; BETA HYDROXYISOVALERYLSHIKON; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TRANSPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SYNERGISM; HUMANS; NAPHTHOQUINONES; ONCOGENE PROTEIN PP60(V-SRC); PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0037114344     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00457-3     Document Type: Article

References (21)

1. Rosenberg B. Anticancer activity of cis-diamminedichloroplatinum(II) and some relevant chemistry. Cancer Treat. Rep. 63:1979;1433-1438.
2. Petsko G.A. Heavy metal revival. Nature. 377:1995;580-581.
3. Chu G. Cellular responses to cisplatin. J. Biol. Chem. 269:1994;787-790.
4. Bellon S.F., Coleman J.H., Lippard S.J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 30:1991;8026-8035.
5. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Loman P.H.M., Reedijk J.A. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantification. Biochemistry. 24:1985;707-713.
6. Hashimoto S., Xu M., Masuda Y., Aiuchi T., Nakajo S., Cao J., Miyakoshi M., Ida Y., Nakaya K. β-Hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL60 cells through a mechanism different from those of Fas and Etoposide. J. Biochem. 125:1999;17-23.
7. Brabec V., Kleinwachter V., Butour J.L., Johnson N.P. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem. 35:1990;129-141.
8. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
9. Kasparkova J., Pospisilova S., Brabec V. Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. J. Biol. Chem. 276:2001;16064-16069.
10. Wang X., Martindale J.L., Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275:2000;39435-39443.
11. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., Jikihara H., Mercola D., Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 274:1999;31648-31654.
12. Giraud-Panis M., Leng M. Transplatin-modified oligonucleotides as modulators of gene expression. Pharmacol. Ther. 85:2000;175-181.
13. Ozanne B., Richards C.S., Hendle F., Burns D., Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinoma. J. Pathol. 149:1986;9-14.
14. Gullick W.J. Prevalence of aberrant expression of the epidermal growth factor. Br. Med. Bull. 47:1991;87-98.
15. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82:1999;241-250.
16. Nishibe S., Wahl M.I., Hernandez-Sotomayor S.M., Tonks N.K., Rhee S.G., Carpenter G. Increase of the catalytic activity of phospholipase C-γ 1 by tyrosine phosphorylation. Science. 250:1990;1253-1256.
17. Margolis B., Rhee S.G., Felder S., Mervic M., Lyall R., Levitzki A., Ullrich A., Zilberstein A., Schlessinger J. EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell. 57:1989;1101-1107.
18. Bjorge J.D., Chan T.O., Antczak M., Kung H.J., Fujita D.J. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc. Natl Acad. Sci. USA. 87:1990;3816-3820.
19. Ahn N.G., Seger R., Bratlien R.L., Diltz C.D., Tonks N.K., Krebs E.G. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase. J. Biol. Chem. 266:1991;4220-4227.
20. Yoshida J., Ishibashi T., Nishio M. Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor. Cancer Res. 61:2001;6151-6157.
21. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970.